A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
about
A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancerAntigen-specific active immunotherapy for ovarian cancerDendritic cell-based cancer immunotherapy for colorectal cancer4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaquesNovel Immunotherapeutic Approaches for Head and Neck Squamous Cell CarcinomaStrategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyondTrial Watch: Toll-like receptor agonists in oncological indications.Recent advances in the development of breast cancer vaccines.Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.New Immunotherapy Strategies in Breast Cancer.Immunotherapy for ovarian cancer.Immunotherapeutic approaches to ovarian cancer treatment.The role of natural killer cells in pulmonary immunosurveillance.Tecemotide: an antigen-specific cancer immunotherapy.Poxviral vectors for cancer immunotherapyCancer testis antigens: A new paradigm for cancer therapy.A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer modelMethods for diversity and overlap analysis in T-cell receptor populations.The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition.Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineA randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.Harnessing the immune system for the treatment of breast cancer.Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm.Immunotherapy strategies in the treatment of breast cancer.Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise.Therapeutic cancer vaccines: a long and winding road to success.Emerging immunotherapy strategies in breast cancer.Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.Immunotherapy for the treatment of breast cancer.The Role of the Immune System in Ovarian Cancer and Implications on Therapy.Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.Specific immunotherapy in ovarian cancer: a systematic review.
P2860
Q22001066-AFE6A3AB-6E1D-4082-BF39-A9500EE1D179Q24193567-E83A687D-5507-4ACF-A81D-11081DDFDDD6Q26751339-A828112F-D16C-4ADF-876E-053C7B7BEAFBQ27314155-770A396F-E606-451B-8110-94B8BFC0F7D1Q28071998-9E826061-F8C2-47E7-A0E4-18B4E0400ED6Q28077815-FFA2C39A-5FB7-4107-B8FB-FCDC4CF137BEQ33878578-E060DB1C-1BDE-4328-9992-0529FCCE802DQ34379303-B4FE0DA6-85F3-4AF1-8059-9985B9AE231CQ34494018-D76EEA37-02BB-4D5F-83B3-E973BBB0B638Q34549227-F73FFDAD-DA0B-439D-BED2-5D4DC967D706Q35164189-98D34B59-1DF3-43F6-A675-2A5ECD78F3A2Q35213535-29AD152C-7F03-4992-AC67-697192EE2A1BQ35549712-42AF0A97-F050-45B7-B46D-8228406E6786Q35886761-8C97921C-83A7-48C8-9B15-DB9F5435D16EQ36350388-FAC1F68B-A8F8-4707-910F-09207AE6E341Q36388554-18924E77-07F9-44EF-B722-A22AF7D46CD2Q36391900-0920D94C-85B5-421C-9F6A-364DFF422143Q36414022-15EAE8EE-0AC4-46E1-B6DA-9BBCA65B08A3Q36527662-582DEBE3-3424-45B1-9991-2674D5EBC24CQ36544576-5A5CCE60-7287-4BDC-A883-7DAC333F578AQ36653524-E4FD711E-6AF8-4F6F-A910-0EA6471F15D9Q36690209-410527C8-1E75-49B2-8254-659DFF9FE232Q36753508-FBDAD3C0-D8BB-4440-B606-ADF04983FA41Q36821095-7D056D8A-30B4-43F4-AC38-5E571B840944Q37224420-E4B5817A-7C29-4010-AB4C-92C953AC2735Q37266006-CE8724F2-4B83-4934-B021-352ED0136DEBQ37476039-A56663FE-87AB-43F8-A6BF-5755A744A937Q37621444-3E77CC6F-40D8-4924-93DF-7C0AFDA7D588Q37989569-85453899-4AB3-44A7-9B92-33760EDE97F7Q38072812-D32F0A14-0A65-4CEB-9FBC-AB57B45F6FADQ38076053-F9332426-7C24-4926-9F9F-35415DA2660EQ38091088-4389955D-A3F7-4B53-854E-B5EBA1A9151FQ38113267-EFDFD522-B913-4CDD-8196-F736D068242AQ38162261-30CE1365-C899-40F3-AFD1-A92274BECB14Q38184650-777BFC1B-2566-44F8-8F06-EC060C87A85EQ38248440-66362A06-570F-44E5-85E3-1A6385BD54BEQ38353772-C5CF55CD-D255-47BE-A515-9402C280E35FQ38715211-0D876706-8931-48C9-B479-FFF1450DAC7DQ38809124-71A8A389-9598-47D3-8D19-676A6369F09CQ38948893-C00E405E-AEEF-49EA-9DF8-1D5CFB6640A6
P2860
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A pilot study of MUC-1/CEA/TRI ...... tic breast and ovarian cancer.
@ast
A pilot study of MUC-1/CEA/TRI ...... tic breast and ovarian cancer.
@en
type
label
A pilot study of MUC-1/CEA/TRI ...... tic breast and ovarian cancer.
@ast
A pilot study of MUC-1/CEA/TRI ...... tic breast and ovarian cancer.
@en
prefLabel
A pilot study of MUC-1/CEA/TRI ...... tic breast and ovarian cancer.
@ast
A pilot study of MUC-1/CEA/TRI ...... tic breast and ovarian cancer.
@en
P2093
P2860
P1476
A pilot study of MUC-1/CEA/TRI ...... tic breast and ovarian cancer.
@en
P2093
Caroline Jochems
Christopher R Heery
Diane J Poole
Elizabeth C Jones
Jacquin Jones
James L Gulley
Jeffrey Schlom
Kwong-Yok Tsang
Mahsa Mohebtash
Mary Pazdur
P2860
P304
P356
10.1158/1078-0432.CCR-11-0649
P407
P577
2011-11-08T00:00:00Z